Home    Back

Rigosertib oral capsules / rigosertib intravenous    (DrugBank: Rigosertib)

1 disease
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa1

36. Epidermolysis bullosa    [ 147 clinical trials,   170 drugs,   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways]
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 147 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03786237
(ClinicalTrials.gov)		January 202114/11/2018Rigosertib for RDEB-SCCA Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell CarcinomaEpidermolysis Bullosa Dystrophica;Squamous Cell CarcinomaDrug: Rigosertib Oral Capsules / Rigosertib IntravenousProf. Johann BauerNULLRecruiting18 Years79 YearsAll12Phase 1;Phase 2Austria